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ABSTRACT 
Background: Increased rates of brain atrophy on serial MRI are frequently used as a surrogate 
marker of disease progression in Alzheimer’s disease and other dementias. However, the extent to 
which they are associated with future risk of dementia in asymptomatic subjects is not clear.  In this 
study, we investigated the relationship between the Cardiovascular Risk Factors, Aging, and 
Dementia (CAIDE) risk score and longitudinal atrophy in middle aged subjects. 
Materials and Methods: A sample of 167 subjects (aged 40-59 at baseline) from the PREVENT-
Dementia programme underwent MRI scans on two separate occasions (mean interval 735 days; SD 
44 days). We measured longitudinal rates of brain atrophy using the FSL Siena toolbox.  
Results: Annual percentage rates of brain volume and ventricular volume change were greater in 
those with a high (>6) vs low CAIDE score – absolute brain volume percentage loss 0.17% (CI 0.07 – 
0.27) and absolute ventricular enlargement 1.78% (CI 1.14 – 2.92) higher in the at risk group. 
Atrophy rates did not differ between subjects with and without a parental history of dementia, but 
were significantly correlated with age. Using linear regression, with covariates of age, sex, and 
education, CAIDE score > 6 was the only significant predictor of whole brain atrophy rates (p=0.025) 
whilst age (p=0.009), sex (p=0.002), and CAIDE > 6 (p=0.017) all predicted ventricular expansion rate. 
Conclusion: Our results show that progressive brain atrophy is associated with increased risk of 
future dementia in asymptomatic middle aged subjects, two decades before dementia onset. 
  
 INTRODUCTION 
It is now clear that pathological changes related to Alzheimer’s disease start decades before 
cognitive symptoms are evident.1, 2 Dementia prevention or postponement strategies, such 
as lifestyle changes, should therefore begin as early as possible and there is a need to 
identify at risk individuals in whom such interventions are likely to have the greatest effect. 
Alzheimer’s disease shares risk factors with vascular disease such as hypertension and 
obesity, and these can be used both to identify individuals at risk, and act as modifiable 
intervention targets. 
A number of dementia risk scores have been suggested 3 including the CAIDE 4 score, which 
was developed in middle aged community dwelling subjects.  
Cross sectional studies have found associations between raised midlife dementia risk scores 
and reduced brain volume.5-8 There has, however, been little reported research on the 
relationship between dementia risk score and subsequent brain atrophy. The aim of this 
study was to investigate to what extent an increased CAIDE score in midlife was linked to 
greater rate of brain atrophy over subsequent years. This is important to determine, since 
brain volume change is a frequently utilised objective biomarker of disease progression used 
in dementia studies, especially for Alzheimer’s disease. It is therefore important to know 
whether it may also be useful as a putative outcome marker for disease progression in 
midlife subjects. 
 
 
METHODS 
Subjects 
The protocol has been described in detail elsewhere.9 A total of 193 participants aged 40 to 59, of 
whom 168 had repeat MRI were recruited through multiple sources. Initially they were identified 
from the dementia register database held at a London National Health Service (NHS) Trust, part of 
the UK National Health Service. This registry holds information on patients with dementia and 
cognitive impairment who have consented to be approached for clinical research and their carers 
(often offspring). Other participants were recruited via the Join Dementia Research website 
(https://www.joindementiaresearch.nihr.ac.uk/), through information about the study on the 
Internet and public presentations. The study aimed to recruit approximately half of the subjects with 
a parental family history of dementia and half without. For those with a family history, the estimated 
time to dementia onset was on average 20 years, based on age of parental dementia onset.9 
Dementia Risk Score 
Dementia risk scores were calculated for each participant at baseline using the Cardiovascular Risk 
Factors, Aging, and Incidence of Dementia (CAIDE) score.4 This is a dementia risk score composed of 
weightings by reference to the following variables: age, sex, education, systolic blood pressure, body 
mass index (BMI), total cholesterol, physical activity, and apoE status. Scores vary from 0 to 18. We 
treated this as a binary variable, split according to the group median (DRS <=6). Family history of 
dementia was defined as positive if at least 1 parent had clinically diagnosed dementia and apoE4 
status was regarded as positive for >= 1 ε4 allele. 
Imaging 
Participants underwent multimodal 3 T structural magnetic resonance imaging on a single scanner 
(Siemens Verio) including volumetric T1-weighted scans (176 slices, 1.0 × 1.0 mm, 1.0 mm slice 
thickness, repetition time = 2300 ms, echo time = 2.98 ms, flip angle 9°). Scans were repeated after 
approximately 2 years on the same scanner using the same protocol. 
Percentage brain volume change and ventricular enlargement between the two scans, were 
determined using the FSL siena program (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki).10 Values were then 
divided by the time between scans to give rates per year. Total intracranial volume (ICV) was 
calculated from the sum of grey matter, white matter and CSF segmentation done with SPM12 
(http://www.fil.ion.ucl.ac.uk/spm). All output was manually checked to ensure correct brain 
segmentation, and alignment of baseline / repeat scans. 
 
Statistical analysis 
Brain volume data and clinical variables were analysed with the Statistical Package for Social 
Sciences (SPSS version 19).  Independent t-tests were used to compare groups for continuous 
variables and chi squared test for categorical data. Pearson’s correlation coefficient was used to 
compare continuous variables. Linear regression was used to investigate predictors of brain atrophy 
rates. Residuals were checked by eye to verify normality, heteroscedasticity and absence of non 
linear associations. 
 
Consent and organization of examinations 
Participants were seen at the West London Cognitive Disorders Treatment and Research Unit. Blood 
was taken for apolipoprotein E (APOE) genotyping, with all members of the research and clinical 
teams remaining blind to the result. Approval for the study has been given by the NHS Research 
Ethics Committee London Camberwell St-Giles (REC reference: 12/LO/1023). All participants 
provided informed written consent. 
 
Role of the funding source 
The sponsor had no role in study design, collection, analysis or interpretation of data, nor in the 
writing of the report or decision to submit the paper for publication. 
 
RESULTS 
Of the 193 participants with T1 MR scans at baseline, 168 had a repeat scan. There were no 
significant differences between those with versus without a repeat scan in age (52.0 SD 5.4 vs 51.3 
SD 5.4; t191=0.6, p=0.5), years of education (16.1 SD 3.4 vs 14.7 SD 3.1; t191=1.9,p=0.06) , CAIDE score 
(5.9 SD 2.9 vs 5.7 SD 2.9; t189=0.4,p=0.7), sex (118/168 vs 17/25 female; χ2=0.1, p=0.8), or APOE 
genotype (64/166 vs 6/25 with ε4; χ2=2.0, p=0.16). However, those with repeat imaging were more 
likely to have a parent with dementia (89/168 [53 %] vs. 6/25 [24 %]; χ2=7.3; p=0.007). 
One participant had marked ventricular shrinkage (-26%) between baseline and repeat scan. There 
were no obvious technical problems with this participant’s images.  As this ventricular change was 
more than 3 SD below the mean (+3.6% SD 5.8), this subject was excluded from further analysis. 
Demographic details of the 167 participants included in the longitudinal analysis are shown in table 
1. 
In univariate analyses, there were no significant differences in either ventricular enlargement or 
brain volume change rates between those with versus without a parent with dementia (table 2), or 
between those with vs. without presence of the APOE ε4 allele. Age (table 3) was significantly 
associated with both ventricular enlargement and brain volume change, as was having CAIDE score > 
6. Males had greater rate of ventricular enlargement, but no difference in overall brain volume 
change.  
In a linear regression, including covariates of age, sex, and number of years of education, ventricular 
enlargement was greater in those with CAIDE score > 6, older age at baseline, and male sex (table 4, 
figure 1).  
In the linear regression for brain volume change, CAIDE score > 6 was the only significant predictor 
(table 4), although age was borderline significant.  
 
DISCUSSION 
We found, in this group of middle aged subjects, that having a CAIDE dementia risk score over 6 was 
significantly associated with brain atrophy over a two year period, after controlling for age, sex and 
years of education. The presence of the APOE ε4 allele, or a parent with dementia was not related to 
ongoing brain atrophy.  
Previous studies, using this and other cohorts, have demonstrated significant associations between 
CAIDE and brain volume.5, 6 Data from the Framingham study 11 investigated the effect of individual 
risk factors, and found midlife diabetes associated with faster hippocampal atrophy, rated visually. A 
study with MRI taken up to 30 years apart found midlife CAIDE score associated with longitudinal 
medial temporal lobe atrophy.12 Neither of these showed strong associations with total brain 
volume, however the brain boundary shift technique we utilised is more sensitive to longitudinal 
change than individual volume measurement.13  
We found relatively greater ventricular expansion in male vs female participants. We could not find 
any previous analysis of the effect of sex on ventricular expansion using the siena technique, 
however one paper using ventricular thickness found greater longitudinal expansion in male 
subjects14 and there have been reports of differential trajectories of brain volume changes between 
the sexes in a number of structures.15  Men generally have larger ventricles 16 and it could be that 
either the ventricular enlargement is easier to detect in bigger ventricles (due to fewer partial 
volume effects) or that enlargement is not a linear process, and is greater in bigger ventricles. 
Further research is suggested to verify this finding, and determine the causal factors. 
We did not find an association between APOE ε4 and brain atrophy. A recent large study of amyloid 
deposition and cortical thinning,17 found that middle aged APOE e4 carriers had markedly increased 
rates of amyloid deposition, but that the effect on cortical thinning was minimal. A separate cross-
sectional study also found that the effect of the APOE ε4 on brain volume was only evident in those 
aged over 60. Our findings are in keeping with these studies, suggesting that APOE ε4  predisposes 
individuals to the Alzheimer amyloid cascade, in which brain volume changes appear at a relatively 
late stage.2  
In our analysis, there was a strong univariate association between age and brain atrophy, however, 
CAIDE score > 6 was significantly associated with brain atrophy even after controlling for the linear 
effect of age. A recent paper 18 compared the utility of different dementia risk scores in predicting 
dementia in the large community dwelling Rotterdam study. They concluded that age was the 
component which contributed most to the predictive ability of the scores. However, they were 
unable to assess the effect of age on the CAIDE score, since all of their participants were in the 
oldest age category of the scoring system. They comment that since the CAIDE score was developed 
in middle aged subjects, it may not be appropriate for use in the over 60 age group, since some 
factors such as BMI may be associated with risk in middle age, but protective in later life.19 
A limitation of this study is that due to the relatively young age of the participants, the actual future 
incidence of dementia remains unknown. However, planned longitudinal follow-up should reveal to 
what extent the CAIDE score and brain atrophy relate to ongoing cognitive decline.  
In summary, in order to investigate preventative strategies for dementia, it is necessary to identify at 
risk subjects years before the onset of clinical symptoms. Our results here, showing an association 
between raised CAIDE score in mid-life and longitudinal brain atrophy support the use of the CAIDE 
score in studies such as the FINGER trial 20 for this purpose. They also indicate that serial MRI may be 
a putative outcome measure in future trials aimed at disease prevention, even in this relatively 
young and symptom-free group. 
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Table 1 Subject demographics. Mean (SD) [range] or n/N (%) for the 167 subjects included in the 
longitudinal MRI analysis. 
Age at first scan 52.0 (5.4) [40:59] 
Years education 16.1 (3.4) [0:24] 
CAIDE [N=165] 5.9 (2.9) [0:15] 
CAIDE > 6 [N=165] 71/165 (43%) 
Female  117/167 (70%) 
Parent with dementia 89/167 (53%) 
APOE ε4 [N=165] 64/165 (39%) 
Interval (days) 735 (44) [627:898] 
 
CAIDE = Cardiovascular Risk Factors, Aging, and Dementia risk score 
 
 
  
Table 2 Univariate comparison of annual percentage change in brain volume and percentage change 
of ventricle volume with demographic variables. Negative brain volume change and positive 
ventricular enlargement indicate brain atrophy. 
 Percentage ventricular 
enlargement  
 Percentage brain volume 
change 
 
 No Yes  No Yes  
Male  
N= 50 / 167 
1.42 (2.65) 3.04 (2.29) 
t165 =-3.75; 
p<0.001 ** 
-0.004 (0.35) 0.027 (0.25) 
t165 =-0.56; 
p=0.579 
Parent with 
dementia 
N= 89 / 167 
1.87 (2.47) 1.93 (2.81) 
t165 =-0.14; 
p=0.889 
-0.011 (0.32) 0.020 (0.33) 
t165 =-0.62; 
p=0.537 
APOE4 ε4 allele 
N= 64 / 164 
1.88 (2.65) 1.95 (2.70) 
t163 =-0.17; 
p=0.868 
0.014 (0.34) -0.018 (0.30) 
t163 =0.62; 
p=0.534 
CAIDE > 6 
N= 71 / 165 
1.14 (2.30) 2.92 (2.78) 
t163 =-4.51; 
p<0.001 ** 
0.075 (0.31) -0.096 (0.32) 
t163 =3.46; 
p=0.001 ** 
** p < 0.01 
CAIDE = Cardiovascular Risk Factors, Aging, and Dementia risk score 
  
Table 3 Univariate correlations of annual percentage change in brain volume and percentage change 
of ventricle volume with demographic variables 
 
 Age Years of Education 
Ventricular enlargement % r= 0.31; p<0.001 ** r= 0.01; p=0.857 
Brain volume change % r= -0.25; p=0.001 ** r= 0.05; p=0.513 
 
** p < 0.01 
 
Table 4 Results of linear regression of annual ventricular enlargement rate and percentage brain 
volume change with age, years of education, sex, and CAIDE score> 6 as predictors 
 
Ventricular 
enlargement 
 
 
Brain 
volume 
change   
 
Standardised 
Beta t Sig. 
Standardised 
Beta t Sig. 
Age 0.217 2.660 0.009 -0.168 -1.941 0.054 
Years education 0.102 1.411 0.160 -0.005 -0.064 0.949 
Male Sex 0.226 3.131 0.002 0.107 1.397 0.164 
CAIDE > 6 0.200 2.402 0.017 -0.200 -2.262 0.025 
 
Ventricular enlargement Model: F4,160 = 10.1,  R2 = 0.202 (Adjusted R2 = 0.182) p<0.001 
Brain volume Model: Model: F4,160 = 4.5,  R2 = 0.101 (Adjusted R2 = 0.078) p=0.002 
CAIDE = Cardiovascular Risk Factors, Aging, and Dementia risk score  
FIGURE CAPTIONS 
Figure 1 Ventricular expansion as a function of age. Regression lines show linear fit for 
Cardiovascular Risk Factors, Aging, and Dementia risk score (CAIDE) split by > 6. 
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